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Abstract: A significant bottleneck in drug discovery is the lack of suitable models for sensitive, 
reliable, and rapid assessment of lead molecules in preclinical stages of drug discovery. Human 
pluripotent stem cells (hPSCs) derived either from early human blastocysts (human embryonic 
stem cells) or by reprogramming somatic cells to a pluripotent state (human-induced pluripotent 
stem cells) can be propagated extensively in vitro while retaining the ability to differentiate into 
any specialized cell type within the body. In this review, we discuss how these unique features 
of hPSCs could offer a way of producing relevant in vitro models amenable to high-throughput 
testing for drug discovery. We summarize recent progress in inducing differentiation of hPSCs 
to specific cell types, and describe the ongoing efforts in applying hPSCs and their differentiated 
derivatives in disease modeling, drug discovery, and developmental toxicology. Moreover, we 
review the applications of high-content imaging assays in detecting the changes in the pheno-
type of hPSCs and their differentiated progeny. Finally, we highlight challenges that need to be 
overcome in order for the application of hPSC technology to fully benefit drug discovery.
Keywords: human pluripotent stem cells, drug discovery, high-content assays
Introduction
Drug discovery is an expensive and lengthy process, hampered by high attrition rates 
(∼90%) of new drug candidates.1 Two key factors contributing to attrition are lack of 
efficacy and safety concerns.2 Current preclinical programs for drug safety include 
both in vivo and in vitro tests, with later preclinical stages relying mainly on animal 
data prior to progression into man. Older retrospective reviews estimated that pre-
clinical tests failed to detect adverse drug reactions in humans in as many as 30% of 
cases.3 A more recent review still showed that unacceptable safety is one of the most 
important reasons for failure, accounting for more than half of all project closures, and 
that the majority of these failures occurred before clinical testing.4 This review also 
highlights the importance of having a solid understanding of the drug target biology 
and the disease indication for a successful outcome of a drug project.4
As previously indicated, in vitro models are widely utilized in preclinical develop-
ment, and these are often humanized models. A particular advantage of in vitro assays 
is the opportunity for a high-throughput approach, which would enable filtering out 
unsuitable compounds at early stages of drug development. However, most of the in 
vitro studies use either primary cells or transformed cell lines, and both cell sources 
have significant drawbacks. Primary human lines can be difficult to source, and their 
tendency to senesce rapidly in culture contributes to reduced robustness of in vitro 
assays due to batch-to-batch variability of cells.5  Development of transformed cell 
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Figure 1 A model for drug discovery using patient-derived hiPSCs.
Notes: The process begins with the derivation of hiPSCs from a patient harboring 
a specific disease phenotype. These hiPSCs can then be directed to differentiate to a 
cell type of interest to model the development and progression of the disease. High-
throughput drug screens can identify potential drugs to alleviate/cure the disease.
Abbreviation: hiPSCs, human-induced pluripotent stem cells.
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lines has alleviated the issue of senescence. However, trans-
formed cell lines often harbor large genomic aberrations, 
and consequently, they can significantly differ from the cell 
type or tissue of origin. Thus, there is a significant and urgent 
need for improved assays that can reliably predict human 
response to drugs.
The derivation of human pluripotent stem cells (hPSCs) 
has opened up potential new and powerful avenues to tackle 
the persistent issues in drug development. In this review, we 
summarize the main features that hPSCs posses that make 
them amenable to high-throughput assays for testing drug 
safety and efficacy. Furthermore, we describe the ongoing 
efforts in applying hPSC-based assays to drug discovery 
and delineating the mechanisms of action of new drug 
candidates. Finally, we discuss tools and methods that need 
to be improved to ensure that hPSC-based assays fulfill the 
potential of transforming the landscape of drug discovery.
Characteristics of hPSCs and  
their potential for applications  
in drug discovery
hPSCs include human embryonic stem cells (hESCs) 
derived from early human blastocysts6 and human-induced 
pluripotent stem cells (hiPSCs) created by reprogram-
ming somatic cell types to a pluripotent state.7,8 Several 
important characteristics distinguish hPSCs from either 
primary or immortalized cell lines. hPSCs are karyotypi-
cally normal cells that can grow in culture extensively due 
to their unlimited self-renewing capacity.6 Because of their 
ability to differentiate into any cell type in vitro, hPSCs can 
provide unlimited supply of differentiated cell types.9 This 
unique dual ability to self-renew and to differentiate makes 
hPSCs an ideal source of cells for drug discovery applica-
tions, whereby undifferentiated cells could be expanded and 
directed to differentiate into a cell type of interest (Figure 1). 
For such an approach to be advantageous over the existing 
in vitro models, the expansion and maintenance of large 
numbers of undifferentiated cells and their subsequent dif-
ferentiation to desired cell types must be robust, reliable, 
and efficient. However, efficient mass culture of hPSCs 
has been hampered by a tendency of these cells to undergo 
apoptosis, particularly when plated as single cells or at a low 
plating density.10,11 The molecular mechanism underpinning 
this pronounced susceptibility to apoptosis involves activa-
tion of the Rho-associated coiled-coil-containing kinase 
pathway, which in turn causes actomyosin hyperactivation 
of dissociated cells.11,12 More recently, hPSCs were also 
shown to have constitutively activated Bax, a proapoptotic 
protein that controls activation of caspases.13 The priming 
for cell death in early embryonic cells may have evolved 
as a protection mechanism against genetic damage in the 
developing embryo.14,15 However, in the context of in vitro 
culture, poor viability of cells creates conditions for culture 
adaptation, whereby genetic variants harboring mutations that 
allow cell growth under suboptimal conditions may expand 
and overtake the culture.16–19 Differences in the behavior 
of culture-adapted cells compared to their wild-type coun-
terparts, including resistance to apoptosis20,21 and reduced 
tendency to differentiate,22,23 could be detrimental if variant 
cells were to be used in applications such as drug screening 
and toxicology. Hence, the issue of culture adaptation brought 
sharply into focus the need for optimizing culture conditions 
for hPSC expansion and maintenance.
The first hPSC lines were derived and maintained in 
two-dimensional culture system on feeder layers of mitoti-
cally inactivated mouse embryonic fibroblasts (MEFs) in 
a medium supplemented with fetal bovine serum.6 Factors 
contained within the serum and secreted by MEFs support 
the self-renewal of hPSCs. However, such ill-defined culture 
conditions are highly undesirable for downstream applica-
tions of hPSCs as they create variability and may introduce 
harmful pathogens. The search for improved and chemically 
defined conditions for hPSCs growth revealed their depen-
dency on fibroblast growth factor (FGF) and Activin/Nodal 
signaling.24,25 Bone morphogenetic protein 4 (BMP4) is an 
inductive signal for differentiation of hPSCs,26 in contrast to 
its role in blocking differentiation of mouse PSCs.27 These 
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Figure 2 hPSCs can differentiate to derivatives of all three embryonic germ layers (ectoderm, mesoderm, endoderm).
Notes: Drug discovery requires directed differentiation of hPSCs to pharmaceutically relevant cell types. The initial directions are mesendoderm and ectoderm through the 
combined activation or inhibition of TGFβ/Activin A/Nodal and BMP pathways, respectively. Further differentiated cell types can then be derived, again through the activation 
or inhibition of signaling pathways. These methods employ the use of both recombinant proteins and chemical inhibitors.
Abbreviations: hPSCs, human pluripotent stem cells; TGFβ, transforming growth factor beta; BMP, bone morphogenetic protein; FGF, fibroblast growth factor; Shh, sonic 
hedgehog; VEGF, vascular endothelial growth factor; DKK1, Dickkopf-related protein 1; EGF, epidermal growth factor; RA, retinoic acid.
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and additional findings provided a basis for development of 
chemically defined media which generally use high concen-
trations of FGF2 or FGF2 in combination with transform-
ing growth factor beta 1 (TGFβ1), Activin A, or a BMP 
 antagonist.28–32 Chemically defined supportive substrates, 
such as laminin 521 and vitronectin, have also been success-
fully used to replace non-defined substrates such as Matrigel 
or MEFs.28,33 The development of chemically defined con-
ditions will be tremendously important for efforts aimed at 
discerning the molecular cues that underpin stem cell fates. 
Nonetheless, the conventional two-dimensional cultures of 
adherent hPSCs may not be suitable for efficient produc-
tion of large numbers of cells for drug discovery or clinical 
applications. Large-scale culture systems could be further 
improved by optimizing three-dimensional bioreactor-based 
propagation of hPSCs in suspension cultures.34–36
Characterization of hPSCs is based on a number of mor-
phological and molecular features. Undifferentiated hPSCs 
display a high nucleus-to-cytoplasm ratio, and they express 
a repertoire of molecular markers. In addition to core pluri-
potency transcription factors POU5F1 (POU domain, class 5, 
transcription factor 1; also known as octamer-binding tran-
scription factor 4 [OCT4]) and NANOG, hPSCs also express 
a series of cell-surface antigens, including globoseries gly-
colipid antigens, stage-specific embryonic antigens 3 and 4 
(SSEA3 and SSEA4), and glycoprotein antigens TRA-1-60, 
TRA-1-81, Thy-1, and GCTM2.37,38 Although the use of cell-
surface antigens provides the possibility of isolating desired 
populations using magnetic beads or fluorescence-activated 
single-cell sorting, none of the markers identified as yet are 
truly specific for hPSCs. Hence, multiple markers must be 
used in combinations to achieve purification of undifferenti-
ated stem cells from their differentiated progeny.
Signaling and directed 
differentiation in hPSCs
Harnessing the immense developmental potential of hPSCs 
in applications such as drug discovery relies on the ability 
to direct differentiation of hPSCs to particular specialized 
cell types. The specification of hPSCs is controlled by the 
interaction and balance of signaling pathways that can be 
manipulated through the use of chemical inhibitors and/or 
recombinant proteins (Figure 2). The first stage in differenti-
ating hPSCs toward a cell type of interest is the selection of 
one of the three primary germ layers (endoderm, ectoderm, 
and mesoderm). In the mouse, it is understood that cells des-
tined for definitive endoderm or mesoderm transition through 
a stage known as mesendoderm within the primitive streak.39 
These cells migrate throughout the embryo and depend-
ing upon their location will form definitive endoderm and 
mesoderm. Mesendoderm germ layer specification relies on 
the activation and interaction of the TGFβ, FGF, BMP, and 
Wnt signaling pathways.40 In hESCs, D’Amour et al showed 
that TGFβ activation through recombinant Activin A, in 
combination with low serum concentrations, was sufficient to 
induce up to 80% of cells expressing the endodermal marker 
SOX17.41 FGF signaling through mitogen-activated protein 
kinase (MAPK) was later found to further improve definitive 
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endoderm specification.42 Furthermore, FGF2, through MEK/
ERK, has been shown to switch BMP4-induced differentia-
tion to the mesendoderm lineage through the maintenance 
of NANOG expression.43 BMP4 functions to aid the rapid 
downregulation of stem cell markers, in particular SOX2 
(a neural marker), and an enrichment of definitive endoderm 
markers EOMES and SOX17. Mesoderm similarly relies on 
the same signaling pathways but has shown to be tempo-
rally dependent upon BMP4 exposure.44 Using Brachyury 
as a pan-mesoderm marker, Zhang et al demonstrated that 
a short exposure time of BMP4 to hESCs leads to maximal 
Brachyury expression.44 A seemingly fundamental differ-
ence between endoderm and mesoderm specification is the 
activation levels of TGFβ/Activin/Nodal signaling, whereby 
a low concentration of Activin A (10–50 ng/mL) effectively 
induces the mesodermal markers Goosecoid45 and MIXL146 
in reporter cell lines. The generation of ectoderm requires 
the inhibition of the aforementioned signaling pathways. 
Initial studies in the frog demonstrated that inhibitors of the 
BMP pathway through Noggin were imperative for neural 
induction.47,48 This effect was later confirmed in mammalian 
cells, and it is now used in hPSC neural induction protocols.49 
The generation of chemical inhibitors, including dorsomor-
phin, then provided a cost-effective way to potently inhibit 
the BMP pathway and further improve neural specification 
in hPSCs.50 However, the inhibition of BMP alone is not 
entirely sufficient. These protocols also require the inhibi-
tion of the TGFβ/Activin/Nodal pathway, using the chemi-
cal inhibitor SB431542.51 Using a combination of Noggin 
and SB431542, Chambers et al demonstrated much higher 
level of PAX6+ cell derivation than either inhibitor singly.52 
Further differentiation protocols then allow the specifica-
tion of pharmaceutically relevant cell types. For example, 
embryoid bodies have shown spontaneous hepatocyte speci-
fication through upregulation of markers such as albumin and 
AFP53 as well as cardiomyocyte specification54 using markers 
such as NKX2.5 and TNNI3, as reviewed by Matsa et al and 
 Denning and Anderson.55,56
Directed differentiation offers a much more powerful 
approach than spontaneous differentiation for deriving 
particular cell types due to reproducibility, homogeneity, 
and efficiency. Hepatocyte specification using insulin with 
dexamethasone57 and sodium butyrate58 has been reported. 
 Similarly, cardiomyocytes have been specified through 
Activin A and bFGF treatment54 using a stepwise differ-
entiation protocol using Activin A, BMP4, FGF, vascular 
endothelial growth factor, and DKK1,59 as well as the use 
of chemical inhibitors such as P203580 (P38 MAPK inhibi-
tor)60 and 5-aza-2′-deoxy-cytidine to enhance specification.61 
Insulin-producing cells have been derived through epidermal 
growth factor, FGF, and Noggin treatment.62,63 From early 
neural cells, dopaminergic neurones have been derived 
through the manipulation of sonic hedgehog (Shh) and 
Wnt864,65 and motor neurones through Shh and retinoic acid 
addition.66 Improved differentiation protocols are continually 
appearing allowing the potential use of many more cell types 
in drug discovery/toxicology, and this continued ability to 
derive new cell types will facilitate the identification and 
screening of new drugs.
hPSC-derived cells for disease 
modeling and drug discovery
Prior to 2006, disease modeling using hPSCs was based 
around either the genetic modification of hESC lines or the 
generation of a new line from embryos exhibiting monogenic 
diseases. Inevitably, few diseases have been investigated this 
way due to severe restrictions of these methods.67 Since the 
generation of hiPSCs, disease modeling has exploded and is 
regarded as one of the most exciting applications of hPSCs. 
hiPSCs from diseased patients can be used to follow disease 
progression as well as allow testing of compounds to allevi-
ate or even cure specific diseases. The first reported instance 
of the use of hiPSCs in disease modeling was in the case of 
spinal muscular atrophy.68 Ebert et al were able to show that 
a mutation within the spinal muscular atrophy gene did not 
affect motor neuron specification; however, motor neuron 
production was hindered, and degeneration increased at 
later time points. Additionally, the compounds valproic acid 
and tobramycin were able to partially rescue the decrease in 
SMN protein production within diseased hiPSCs.68 The use 
of hiPSCs in amyotrophic lateral sclerosis (ALS) modeling 
yielded kenpaullone as a candidate compound to reduce 
the levels of mutant SOD1 protein within affected motor 
neurons.69 Kenpaullone, a GSK3β inhibitor, was the only 
one of many GSK3β inhibitors tested to have this protective 
effect; therefore, the mechanism of action presumably did not 
lie solely within GSK3β inhibition. The authors identified 
that kenpaullone also inhibits HPK1/GCK-like kinase (also 
known as MAP4K4), which prevents the activation of an 
apoptotic pathway involving phospho-c-Jun.69 To screen for 
new candidate drugs for treatment of ALS, Egawa et al pro-
duced spinal motor neurons from  ALS-hiPSC lines derived 
from ALS patients with mutations in Tar  DNA-binding 
protein-43. The ALS motor neurons were then tested against 
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a panel of four compounds, and anacardic acid was identi-
fied as a drug that alleviated the disease phenotype of ALS 
motor neurons.70 Although performed on a limited set of 
compounds, the screen by Egawa et al demonstrated feasi-
bility of using patient-specific hiPSC-derived cells in drug 
discovery for ALS therapies.
Another first was the use of hPSCs in modeling famil-
ial Alzheimer’s disease (FAD) that is caused by mutations 
primarily in the PS1 gene, although PS2 mutations are also 
documented.71,72 Pathologically, this leads to neural loss and 
accumulation of amyloid fibril plaques, mainly β-amyloid. 
hiPSCs were generated and differentiated to neurons to 
explore pathological events in FAD. Neuronal development 
was not hindered by PS1 or PS2 mutant hiPSC lines, but the 
cells did excrete higher levels of β-amyloid. Cell lines from 
both mutations were respondent to several chemicals which 
could reduce the levels of β-amyloid, and these lines could 
be particularly useful in drug screening for the treatment of 
FAD.73 Similarly, Lee et al derived hiPSC lines from patients 
suffering familial dysautonomia,74 caused by a point mutation 
in the IKBKAP gene and subsequent mis-splicing.75 They 
found particularly high levels of the mis-spliced version of 
IKBKAP in endodermal precursors, which they attribute to 
the debilitating gastrointestinal defects of affected individu-
als, as well as in neural crest, which also showed a significant 
decrease in genes for neurogenesis, neuronal differentiation, 
and migration.74 In a subsequent study, Lee et al have utilized 
hiPSC-derived neural crest precursors from familial dysauto-
nomia patients in a primary screen of 6,912 small-molecular 
weight compounds and identified several hits that rescue IKB-
KAP expression and may represent candidates for developing 
therapies.76 A similar high-throughput screening effort of 
3,131 compounds was performed on hiPSC-derived hepatic 
cells from a patient suffering from a liver disorder due to 
alpha-1 antitrypsin deficiency.77 The use of a high-throughput 
approach in these studies is an important step toward scaling 
up the hiPSC-based drug discovery to screening of more 
comprehensive chemical libraries.76,77
The understanding of disease mechanisms also allows 
for a much more informed prediction for drug treatment of 
specific diseases. For example, schizophrenia is a genetically 
and pathologically complicated disease with wide-ranging 
symptoms. One possible cause lies with the reduction of 
GAD6778,79 and GAT180 leading to a reduction of GABA 
synthesis and reuptake of GABA in approximately 25%–30% 
of GABA neurons. Drugs whose function causes the augmen-
tation of the release of GABA, or enhances the response to 
GABA, such as the GABA
A
 α2-selective benzodiazepine, 
may prove to be specific and effective in alleviating disease 
symptoms.81 hiPSC lines have been derived from schizo-
phrenic patients82 and may therefore prove to be useful in 
validating and discovering such drugs.
Aside from neurological disorders, cardiac diseases 
have been modeled using hiPSCs. Cardiomyocytes and 
smooth muscles cells derived from hiPSCs of patients with 
cardiovascular diseases generally demonstrate the disease 
phenotype in vitro. For example, cardiomyocytes produced 
by differentiation of hiPSCs of LEOPARD syndrome patients 
exhibited increased cell size, indicative of hypertrophic 
cardiac state.83 Similarly, cardiomyocytes have been derived 
from hiPSCs of patients suffering from familial dilated 
cardiomyopathy caused by a mutation in the gene encoding 
cardiac troponin T. hiPSC-derived cardiomyocytes from 
patients exhibited a number of features characteristic of 
the disease phenotype, including altered regulation of calcium 
ion, decreased contractility, and changes in the distribution 
of sarcomeric proteins.84 Another notable example is long-
QT syndrome, a channelopathy characterized by a delayed 
ventricular repolarization. Principally involving mutations 
in myocyte ion-channels, long-QT syndrome can lead to 
sudden arrhythmic death.85 hiPSC lines generated from 
affected patients displayed prolonged action-potential dura-
tion as well as early-after depolarizations, representative of 
human disease pathology.86 Upon the addition of nifedipine, 
action-potential duration and early-after depolarizations were 
reversed and abolished, respectively.86 Strikingly, however, 
the prolonged exposure of nifedipine leads to the cessation 
of beating within some embryoid bodies.86 Long-QT syn-
drome hiPSCs can thus also act as a platform for predictive 
cardiotoxicity. Therefore, disease modeling allows greater 
understanding of the pathogenesis of specific diseases, but 
also allows a detailed interrogation of the mechanisms behind 
disease phenotypes. This allows the identification of exist-
ing drug candidates in ameliorating disease symptoms, but 
will also allow the development of new, novel drugs targeted 
against specific proteins or signaling pathways. Nonetheless, 
an often overlooked caveat of the hiPSC approach for disease 
modeling is the use of appropriate controls. The controls 
for known, monogenic diseases can be created relatively 
easily by replacing the mutated gene with its wild-type 
form.87,88 However, the modeling of more complex diseases 
or diseases with an unknown etiology is complicated by 
the fact that even sibling controls may be inappropriate as 
the genetic background will be different and may influence 
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the cell phenotype, thus warranting a careful consideration 
of experimental controls.89
The use of hPSCs as models  
for developmental toxicology
Some of the most devastating consequences of adverse drug 
effects include birth anomalies caused by drug exposure of a 
developing fetus. These effects are potentially preventable, 
but the issue of fetal exposure is compounded by the fact 
that pregnant women may be ingesting drugs before they 
realize they are pregnant, and drugs that manifest no adverse 
reactions in adults may still cause defects during prenatal 
development. On the other hand, avoidance of all drugs 
during pregnancy may be detrimental for women with 
preexisting medical conditions or medical problems. In 
order to assess the effects of a compound on the developing 
conceptus, the developmental safety of a compound is tradi-
tionally evaluated using in vivo studies in pregnant animals 
which generally include a rodent species (usually rat) and 
a non-rodent species (usually rabbit), usually with preterm 
evaluation of fetuses.90 Compound exposure is conducted 
during embryo organogenesis between the stage of implan-
tation of the conceptus and the closure of the hard palate. 
Assessment at the end of gestation just prior to parturition is 
conducted for developmental external, visceral, and skeletal 
endpoints on fetuses. The traditional in vivo testing method 
based on extrapolating across dose and species to human 
has been regarded as effective91 ever since the thalidomide 
disaster in the 1960s. However, there is a widespread desire 
to develop alternate (nonmammalian) methods that can pro-
vide data more quickly, using less compound and reducing 
in vivo testing.
Ordinarily in the pharmaceutical industry, efficacy and 
general toxicity are assessed much earlier than developmen-
tal toxicity. In the last decade, efforts have been made to 
try to find alternative in vitro methods, which would allow 
screening of many compounds early in the pharmaceutical 
pipeline to evaluate developmental endpoints prior to the 
mammalian assays. Some of these in vitro methods have the 
potential to screen thousands of compounds for their effects 
on complex pathways relevant to developmental processes 
and toxicities.92 Many possible models have been explored, 
including hydra regeneration,93 chick embryo neural retina 
cells,91,94 embryonic palatal mesenchymal cells,95 mouse 
ovarian tumor cell attachment,96 chick embryos,97 whole rat, 
mouse or rabbit embryo culture in vitro,98–101 mouse palatal 
cultures,102 mouse limb bud reaggregates,103 in vivo larval 
zebrafish assays,104,105 and ESCs.106,107
In some laboratories, murine ESCs were the model of 
choice for developmental toxicology studies. A murine ESC 
platform based on adherent-cell differentiation culture108 
monitored both cytotoxicity and myosin heavy-chain protein 
expression as a marker of cardiomyocyte differentiation 
that is dependent upon diverse cellular interactions across 
different primary germ layer lineages. Alternatively, in the 
“embryonic stem cell test” (EST), the use of murine ESCs 
(D3 cell line) cultured to form embryoid bodies focusing 
on the differentiation of beating cardiomyocytes as a visual 
endpoint marker, and additionally the relative effects on 
D3 and adult fibroblast cells (3T3) cytotoxicity, was shown 
to have the ability to predict the developmental toxicity of 
78% of 20 compounds in a test panel.109,110 Both of these 
assays, the EST and murine ESC platforms,108 may provide 
important information about chemical effects on complex 
differentiation pathways in murine systems. This information 
should be, to a degree, translatable to a human, as seen with 
in vivo animal models, providing an insight into the potential 
developmental effects seen at a cellular level. However, the 
use of hESCs should alleviate species-specific differences 
between mouse and humans and therefore is expected to 
increase the predictive power of the developmental toxicity 
testing. Several proof-of-concept studies exposed hESCs to 
known developmental toxicants and ascertained the validity 
of this model.111,112
Profiling hESCs for their secreted metabolites has been 
proposed as an alternative testing platform for identifying 
compounds with developmental activity.113,114  Metabolomics 
detects dynamic variations in small molecule abundance, 
assessing functional changes in biochemical pathways and 
cellular metabolic response due to chemical exposure. Taking 
this into consideration, the profile of intermediary metabolites 
and small molecules released by hESCs to their environment 
(“secretome”) is therefore potentially a direct or indirect indi-
cator of chemical disruptions that could lead to identification 
of the extent of adverse outcome pathways in the develop-
ing embryo. On the whole, the metabolome for stem cells is 
characterized by changes in metabolites involved in cellular 
respiration. The metabolome of hiPSCs has been shown to 
share a pluripotent metabolomic signature with hESCs that is 
distinct from their parental cells.115 However, some metabo-
lites do differ between hiPSCs and hESCs, which reveal novel 
metabolic pathways that play a critical role in regulating 
somatic cell reprogramming.116 The identification of specific 
small molecule biomarkers of chemical exposure or effect 
could provide valuable mechanistic information and pinpoint 
sensitive pathways in early human embryogenesis.117,118 
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Assay setup: treatment of hPSCs with control and test compounds
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Figure 3 High-content imaging of hPSCs allows detection of cell phenotypes based 
on cell numbers, morphology, and marker staining.
Notes: (A) A workflow of a high-content primary screen on hPSCs. (B) Human 
ESC colonies grown on Matrigel in mTESR, stained for markers of undifferentiated 
state OCT4 (POU5F1, green) and SSeA3 (red). Nuclei are counterstained with 
Hoechst 33342. The absence of OCT4 and SSeA3 staining in some cells is indicative 
of spontaneous differentiation. Images were obtained with the InCell Analyzer 2000 
(Ge Healthcare) high-content imaging platform. Scale bar, 200 µm.
Abbreviations: hPSCs, human pluripotent stem cells; eSC, embryonic stem cell; 
OCT4, octamer-binding transcription factor 4; SSEA3, stage-specific embryonic 
antigen 3.
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In addition, the application of metabolomics to developmental 
toxicity testing is also  possible.113 The application of the hESC 
secretome to predictive developmental toxicity (devTOX 
platform – Stemina) has been described.114 The devTOX 
platform was shown to accurately predict 88% of compounds 
with known developmental toxicity out of a test set of eight 
teratogenic compounds.114
Approaches to high-throughput and 
high-content screening of hPSCs and 
their derivatives in drug discovery
Maintenance of genetically stable undifferentiated hPSCs in 
culture and their differentiation to relevant cell types is an 
important first step in addressing the lack of suitable in vitro 
models for drug discovery. However, challenges additional 
to the availability of appropriate cellular models need to be 
addressed in order for this resource to provide significant 
improvements in drug discovery campaigns. In particular, 
screening assays have to be sensitive and robust, but also 
suitable for high-throughput analyses. The screening assay 
has to be carefully selected from a range of methods, such 
as immunocytochemistry, reverse-transcriptase polymerase 
chain reaction, dot-blot analysis, and luminescence, depend-
ing on the nature of the signal that needs to be assessed. Plate 
reader-based assays, albeit rapid, have significant shortfalls 
for cellular phenotyping as they usually provide only a single 
readout from a population of cells.119 This type of a readout 
assumes a homogeneous population of cells and average pop-
ulation data. However, it is becoming increasingly apparent 
that even genetically identical populations of cells can have 
heterogeneous phenotypes, and that such heterogeneity has 
functional implications.120–122 Thus, drug screening assays 
have to be able to detect potentially differential response of 
genetically identical cells to treatments. This requires cell-by-
cell analysis that can unmask the heterogeneity obscured by a 
single average population readout.120 Flow cytometry-based 
assays offer this possibility through single-cell analysis of 
cells labeled with a range of antibodies and stains, resulting 
in a multivariate profiling of each cell. Nonetheless, flow 
cytometry requires dissociation of adherent cells, potentially 
losing valuable information on cell morphology. As corollary 
of a limited readout and/or lack of morphological measure-
ments and spatial signals, unanticipated effects of drugs’ 
effects on cells will go undetected until a later stage of drug 
discovery, possibly contributing to high rates of late-stage 
attrition. Extensive evaluation of new lead compounds early 
on in a drug development process would significantly reduce 
the overall cost and efforts, and would allow selection of 
candidates with the best prospect of success in the clinical 
stages of drug discovery.
High-content imaging assays (Figure 3) have emerged as 
a powerful tool for extensive assessment of cell phenotypes 
through simultaneous, quantitative measurements of a vari-
ety of cell parameters.123 In a typical high-content chemical 
screening assay, cells are plated into multi-well plates and 
treated with control compounds or drugs from a chosen drug 
library for a predetermined period of time. Cells are then fixed 
and stained with a number of antibodies and/or cellular dyes. 
Fluorescent imaging of labeled cells and the subsequent image 
analyses allow numerous readouts and hence multiparametric 
assessment of cells, including the presence of antigen(s) of 
interest and their subcellular localization, cell numbers, size, 
and shape. Indeed, the term “high content” was coined to 
reflect such a large amount of information obtained from 
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imaging of individual cells. Unlike the target-based approach, 
high-content cell-based assays make no a priori predictions 
as to the targets involved. This type of a hypothesis-free 
screening allows an unbiased assessment of cell phenotype 
and detection of changes in features that may be missed in an 
assay with just a single readout. Importantly, due to the fact 
that a single high-content assay integrates various readouts, 
which would otherwise require testing in multiple individual 
assays, high-content analysis significantly improves the speed 
and reduces the cost of cellular  phenotyping. Both the cost 
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and speed of high-content assays are even further improved 
by automating majority of steps, from cell plating to image 
analysis. Automated image analysis also contributes to 
achieving robust and objective readouts. The sensitivity of 
high-content assays stems from the fact that the data are 
derived from single-cell measurements and can detect subtle 
changes within a cell population.124–126
Given the power of the high-content approach, it is not 
surprising that high-content assays have not only become an 
integral part of drug discovery screens but are also utilized 
by academic researchers investigating various aspects of 
cell biology. Indeed, high-content assays have been success-
fully applied toward gaining a better understanding of the 
signaling pathways involved in survival and differentiation 
of hPSCs. An illustrious example is a screen by Desbordes 
et al, which assessed effects of 2,880 small-molecular 
weight compounds on hPSCs. The screen utilized imag-
ing of POU5F1- immunostained cells as a readout of the 
 differentiation-inducing abilities of compounds, and identified 
four inducers and ten inhibitors of differentiation.127 Similarly, 
Andrews et al performed a high-content screen on hPSCs to 
identify compounds that enhance cell survival.128 Although 
high-content platforms for imaging of cells were used in these 
screens, the readouts were limited to the numbers of cells 
and/or cells positive for a marker of undifferentiated state, 
without fully exploiting the power of high-content  screening. 
Barbaric et al devised a high-content assay on hPSCs that, in 
addition to the number of cells and cells positive for  TRA-1-60 
marker of undifferentiated state, assessed number of hPSC 
colonies, their area, and shape as well as the intensity of 
staining.129,130 This type of analysis enabled stratification of 
hits that induce the cell differentiation. For example, although 
all-trans-retinoic acid and steroid compounds induced a 
reduction in TRA-1-60 levels to a similar extent, a significant 
difference in the morphology of the hPSC colonies indicated 
that the differentiation phenotypes were likely to be different, 
and this was indeed confirmed by gene expression analyses.129 
Ultimately, the high-content assays should be able to predict 
which molecular pathways are activated or disrupted upon 
chemical treatment of cells, based on the cell phenotype. To 
demonstrate the feasibility of this approach Perlman et al 
used 96 compounds with known targets, three compounds 
with unknown mechanism, and a compound with multiple 
known targets. High-content multivariate phenotyping of 
cells enabled clustering of molecules based on the pheno-
typic effects they induced in the cells.131 A pertinent question 
in high-content screening is how many and which cellular 
features should be measured from images? Given that high-
content imaging offers the opportunity to extract hundreds of 
phenotypic measurements of each cell, the temptation may 
be to include as many features as possible; nonetheless, large 
datasets produced would not only be computationally chal-
lenging but may in fact reduce the sensitivity of the assay. Loo 
et al addressed this issue by reducing the set of approximately 
300 features to approximately 20 readouts that could reliably 
discriminate between different sets of compounds on cancer 
cells.124 Similar analyses on hPSCs and their differentiated 
derivatives should be performed to define the minimal feature 
sets that would allow fast yet sensitive and reliable identifica-
tion of compounds that perturb the cell phenotype.
Most high-content assays are performed as fixed-end 
point assays, and as such, they may not be suitable for detect-
ing dynamic temporal changes in cellular behavior. The 
addition of time dimension offers the opportunity to acquire 
additional information on cell behavior (Figure 4). A case 
in point is cell motility, a feature that plays a significant 
role in the metastatic behavior of cancer cells and may be a 
particularly crucial readout in screens for anticancer drugs.132 
Time lapse-based assays have been employed in screening of 
neural cells,133 but the widespread use of this method awaits 
improvement in automation of cell-tracking protocols, data 
storage, and analysis.134
Conclusion and future perspectives
Identification of suitable preclinical models has emerged 
as a critical element in improving drug discovery. The 
availability of hPSCs offers unprecedented opportunities 
for successful screening of new chemical entities. Perhaps, 
the most exciting prospect is the ability to obtain patient-
specific cells for disease modeling and screening for drugs 
that correct the disease phenotype, thus paving the way to 
individualized treatments.135 Nonetheless, leveraging the 
enormous potential of hPSCs will require optimization 
of differentiation protocols and in-depth characterization 
of the resulting differentiated cells. One aspect that must 
be addressed is the immaturity of cell types derived from 
hPSCs, and whether these can appropriately read out tox-
icity that would manifest within an adult. Implementing 
methods to age cells in vitro may aid in resolving this issue 
and allow modeling of late-onset diseases.136 Moreover, 
further developments are warranted to ensure that culture 
systems accurately recapitulate the in vivo environment of 
cells. Indeed, traditional two-dimensional cell culture sys-
tems generally poorly represent mechanical, chemical, and 
cell–cell interaction cues that cells encounter in their native 
tissues.137 A number of approaches are being developed 
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to address the drawbacks of two-dimensional cell culture, 
including the fabrication of scaffolds with either synthetic 
polymers or natural materials.138 Ultimately, hPSC-derived 
organs-on-chips will provide physiologically relevant mod-
els mimicking different organs amalgamated into a single 
system to mimic the tissue–tissue interaction, and drug 
absorption, metabolism, transport, and clearance.139 Final 
conclusions on the usefulness of such models in preclinical 
drug discovery await further validation studies. Nonetheless, 
examples of hPSC applications in disease modeling and drug 
testing reviewed in this article provide a tantalizing hint that 
we may be at the dawn of a new era in drug discovery.
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